Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Income: 2015-2024

Historic Net Income for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $125.9 million.

  • Seres Therapeutics' Net Income fell 115.63% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year decrease of 184.78%. This contributed to the annual value of $125.9 million for FY2024, which is 64.79% up from last year.
  • According to the latest figures from FY2024, Seres Therapeutics' Net Income is $125.9 million, which was up 64.79% from $76.4 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Net Income ranged from a high of $125.9 million in FY2024 and a low of -$90.1 million during FY2020.
  • In the last 3 years, Seres Therapeutics' Net Income had a median value of $76.4 million in 2023 and averaged $45.2 million.
  • Its Net Income has fluctuated over the past 5 years, first fell by 26.30% in 2020, then skyrocketed by 214.77% in 2023.
  • Yearly analysis of 5 years shows Seres Therapeutics' Net Income stood at -$90.1 million in 2020, then rose by 28.38% to -$64.5 million in 2021, then dropped by 3.17% to -$66.6 million in 2022, then surged by 214.77% to $76.4 million in 2023, then surged by 64.79% to $125.9 million in 2024.